Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit
The proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor types
Myricx Bio's first-in-class NMTi payload platform is designed to improve the therapeutic index of ADCs, offering the potential for more effective and better-tolerated treatment options for cancer patients
The transaction valued at up to $1.5 billion including $1.1 billion cash upfront
